KRYS Financials Krystal Biotech, Inc.
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $389M | $205M | 0.0% | 41.5% | 16.8% | 15.4% | $189M | — | $496M |
| 2024 | $291M | $89M | 0.0% | 22.6% | 9.4% | 8.4% | $119M | — | $345M |
| 2023 | $51M | $11M | 0.0% | -216.2% | 1.4% | 1.3% | -$101M | — | $358M |
| 2022 | $0 | -$140M | — | — | -26.8% | -25.1% | -$154M | — | $162M |
| 2021 | $0 | -$70M | — | — | -11.7% | -11.1% | -$116M | — | $341M |
| 2020 | — | -$32M | — | — | -11.0% | -10.3% | -$41M | — | $268M |
| 2019 | — | -$19M | — | — | -9.4% | -9.1% | -$25M | — | $188M |
| 2018 | — | -$11M | — | — | -9.6% | -9.4% | -$12M | — | $104M |
| 2017 | — | -$8M | — | — | -16.0% | -15.8% | — | — | $50M |
| 2016 | — | -$1M | — | — | -397.9% | -52.7% | — | — | $2M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Sep '26 | $127M | $63M | 0.0% | 55.9% | 4.4% | 4.0% | $90M | — | $463M |
| Jun '26 | $119M | $55M | 0.0% | 49.0% | 4.0% | 3.6% | $71M | — | $428M |
| Mar '26 | $116M | $56M | 0.0% | 46.1% | 4.4% | 4.0% | $73M | — | $501M |
| Dec '25 | $107M | $51M | 0.0% | 41.3% | 4.2% | 3.9% | $75M | — | $496M |
| Sep '25 | $98M | $79M | 0.0% | 42.3% | 7.0% | 6.4% | $38M | — | $393M |
| Jun '25 | $96M | $38M | 0.0% | 41.0% | 3.7% | 3.4% | $51M | — | $354M |
| Mar '25 | $88M | $36M | 0.0% | 41.1% | 3.6% | 3.3% | $25M | — | $309M |
| Dec '24 | $91M | $45M | 0.0% | 45.4% | 4.8% | 4.3% | $52M | — | $345M |
| Sep '24 | $84M | $27M | 0.0% | 26.8% | 3.1% | 2.8% | $58M | — | $374M |
| Jun '24 | $70M | $16M | 0.0% | 12.2% | 1.9% | 1.7% | -$5M | — | $346M |
| Mar '24 | $45M | $932000 | 0.0% | -14.8% | 0.1% | 0.1% | $15M | — | $359M |
| Dec '23 | $42M | $9M | 0.0% | 7.4% | 1.1% | 1.1% | -$9M | — | $358M |
| Sep '23 | $9M | $81M | 0.0% | -303.8% | 10.7% | 10.2% | -$23M | — | $373M |
| Jun '23 | $0 | -$33M | — | — | -5.1% | -4.9% | -$37M | — | $276M |
| Mar '23 | $0 | -$45M | — | — | -9.3% | -8.5% | -$32M | — | $141M |
| Dec '22 | $0 | -$32M | — | — | -6.1% | -5.7% | -$28M | — | $162M |
| Sep '22 | $0 | -$30M | — | — | -5.5% | -5.2% | -$34M | — | $186M |
| Jun '22 | — | -$28M | — | — | -5.0% | -4.7% | -$60M | — | $219M |
| Mar '22 | — | -$50M | — | — | -9.1% | -8.1% | -$33M | — | $269M |
| Dec '21 | — | -$22M | — | — | -3.7% | -3.5% | -$62M | — | $341M |
Valuation over time
How the market has priced KRYS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 301.3× (Jan '24) to 42.8× (Nov '26).
- The price-to-sales ratio has fallen from 65.0× (Jan '24) to 22.5× (Nov '26).
Frequently asked questions
Is KRYS growing its revenue and profit?
See the revenue and net-income charts above for Krystal Biotech, Inc.'s multi-year trend.
How much debt does KRYS have?
As of FY2025, Krystal Biotech, Inc. reported — of total debt against $496M of cash.
What is KRYS's profit margin?
In FY2025, gross margin was —, operating margin 41.5%, and net margin 52.6%.
What is KRYS's P/E ratio?
Krystal Biotech, Inc.'s P/E (TTM) is 38.95 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the KRYS stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 42.8× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.